Lincoln Pharmaceuticals Limited Share Price & Analysis
₹625.55▲ +0.97%Updated 5 Jun 2026, 05:02 pm IST
LTP
₹625.55
+0.97%
Open
₹—
High
₹657
Low
₹620
Close
₹625.55
52W High
₹770
52W Low
₹440
Volume
192K
Lot Size
1
Sector
Healthcare
Market Cap
₹1K Cr
Face Value
₹10
Small Cap
Price Chart
Fundamentals
P/E
13.3
Sector P/E
48.9
P/B
1.65
EPS
₹43.89
ROE
12.3%
ROCE
16.3%
D/E Ratio
0
Div Yield
0.31%
Book Value
₹378
+
Strengths
- ✓Efficient capital deployment (ROCE 16.3%)
- ✓Attractively valued vs sector (P/E 13.3x vs industry 48.9x)
- ✓Virtually debt-free
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,783 | ₹4.3L Cr | 34.4 | 5.12 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹6,616 | ₹1.7L Cr | 66.1 | 10.48 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,416 | ₹1.5L Cr | 66.4 | 17.81 | 27.6 | 15.4 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,315 | ₹1.2L Cr | 59.5 | 12.62 | 22.1 | 17.9 | 0.88 |
| CIPLA Cipla Limited | ₹1,402 | ₹1.1L Cr | 27.3 | 3.29 | 12.4 | 16.6 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,091 | ₹1.1L Cr | 20 | 4.05 | 21.2 | 21.2 | 0.38 |
| DRREDDY Dr. Reddy's Laboratories Limited | ₹1,283 | ₹1.1L Cr | 25.4 | 2.83 | 11.8 | 13.6 | 0.16 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
LINCOLN · as of Mar 2026
Promoters49.78%
FII5.00%▼0.16
Public45.23%▲0.16
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 49.81% | 49.54% | 49.78% | 49.78% | 49.78% | 49.78% |
| FII | 3.22% | 3.93% | 3.95% | 5.19% | 5.16% | 5.00% |
| DII | 0.06% | 0.05% | 0.04% | — | — | — |
| Public | 46.92% | 46.49% | 46.24% | 45.04% | 45.07% | 45.23% |
Corporate Events
Dividend - Rs 1.80 Per Share
Dividend11 Sept 2025
Dividend - Rs 1.80 Per Share
Dividend12 Sept 2024
Annual General Meeting/Dividend - Rs 1.50 Per Share
Dividend14 Sept 2023
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹166 Cr ▲1.8% | ₹163 Cr ▲5.8% | ₹154 Cr ▼8.3% | ₹168 Cr ▲14.3% | ₹147 Cr ▼8.7% | ₹161 Cr ▲9.5% | ₹147 Cr ▲3.5% | ₹142 Cr |
| Op. Profit | ₹24 Cr ▼4.0% | ₹25 Cr ▲4.2% | ₹24 Cr ▼11.1% | ₹27 Cr ▲12.5% | ₹24 Cr ▼14.3% | ₹28 Cr ▲21.7% | ₹23 Cr ▲27.8% | ₹18 Cr |
| OPM | 14.0% ▼12.5% | 16.0% ▲6.7% | 15.0% ▼6.3% | 16.0% ▲0.0% | 16.0% ▼11.1% | 18.0% ▲20.0% | 15.0% ▲15.4% | 13.0% |
| Net Profit | ₹29 Cr ▲45.0% | ₹20 Cr ▼28.6% | ₹28 Cr ▲133.3% | ₹12 Cr ▼42.9% | ₹21 Cr ▼19.2% | ₹26 Cr ▲8.3% | ₹24 Cr ▲26.3% | ₹19 Cr |
| EPS (₹) | 14.28 ▲43.1% | 9.98 ▼27.8% | 13.82 ▲139.1% | 5.78 ▼44.3% | 10.37 ▼21.1% | 13.15 ▲11.3% | 11.82 ▲27.2% | 9.29 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹623 Cr ▲7.2% | ₹581 Cr ▲13.9% | ₹510 Cr ▲8.1% | ₹472 Cr ▲11.3% | ₹424 Cr ▲9.8% | ₹386 Cr ▲5.5% | ₹366 Cr ▲1.4% | ₹361 Cr ▲0.3% | ₹360 Cr |
| Expenses | ₹522 Cr ▲8.8% | ₹480 Cr ▲14.0% | ₹421 Cr ▲12.0% | ₹376 Cr ▲11.6% | ₹337 Cr ▲5.0% | ₹321 Cr ▲7.4% | ₹299 Cr ▼2.9% | ₹308 Cr ▼1.6% | ₹313 Cr |
| Op. Profit | ₹102 Cr ▲2.0% | ₹100 Cr ▲11.1% | ₹90 Cr ▼6.3% | ₹96 Cr ▲10.3% | ₹87 Cr ▲31.8% | ₹66 Cr ▼2.9% | ₹68 Cr ▲28.3% | ₹53 Cr ▲12.8% | ₹47 Cr |
| OPM | 16.0% ▼5.9% | 17.0% ▼5.6% | 18.0% ▼10.0% | 20.0% ▼4.8% | 21.0% ▲23.5% | 17.0% ▼5.6% | 18.0% ▲20.0% | 15.0% ▲15.4% | 13.0% |
| Other Income | ₹22 Cr ▼35.3% | ₹34 Cr ▲54.5% | ₹22 Cr ▲120.0% | ₹10 Cr ▲100.0% | ₹5 Cr ▼54.5% | ₹11 Cr ▲120.0% | ₹5 Cr ▲0.0% | ₹5 Cr ▲150.0% | ₹2 Cr |
| Interest | ₹2 Cr ▲100.0% | ₹1 Cr ▼50.0% | ₹2 Cr ▲100.0% | ₹1 Cr ▼50.0% | ₹2 Cr ▲0.0% | ₹2 Cr ▼50.0% | ₹4 Cr ▼20.0% | ₹5 Cr ▼28.6% | ₹7 Cr |
| Depreciation | ₹13 Cr ▲18.2% | ₹11 Cr ▲22.2% | ₹9 Cr ▲12.5% | ₹8 Cr ▲0.0% | ₹8 Cr ▲14.3% | ₹7 Cr ▲0.0% | ₹7 Cr ▲16.7% | ₹6 Cr ▲0.0% | ₹6 Cr |
| PBT | ₹109 Cr ▼10.7% | ₹122 Cr ▲22.0% | ₹100 Cr ▲4.2% | ₹96 Cr ▲14.3% | ₹84 Cr ▲25.4% | ₹67 Cr ▲8.1% | ₹62 Cr ▲34.8% | ₹46 Cr ▲24.3% | ₹37 Cr |
| Tax % | 25.0% ▲4.2% | 24.0% ▼11.1% | 27.0% ▼3.6% | 28.0% ▲7.7% | 26.0% ▲13.0% | 23.0% ▲4.5% | 22.0% ▼12.0% | 25.0% ▲0.0% | 25.0% |
| Net Profit | ₹82 Cr ▼11.8% | ₹93 Cr ▲27.4% | ₹73 Cr ▲5.8% | ₹69 Cr ▲11.3% | ₹62 Cr ▲21.6% | ₹51 Cr ▲4.1% | ₹49 Cr ▲40.0% | ₹35 Cr ▲25.0% | ₹28 Cr |
| EPS (₹) | 41.11 ▼11.7% | 46.58 ▲28.0% | 36.4 ▲5.1% | 34.63 ▲11.3% | 31.12 ▲21.0% | 25.72 ▲5.6% | 24.36 ▲40.7% | 17.31 ▲23.1% | 14.06 |
| Div Payout | 4.0% ▲0.0% | 4.0% ▲0.0% | 4.0% ▲0.0% | 4.0% ▼20.0% | 5.0% ▼16.7% | 6.0% ▲0.0% | 6.0% ▼33.3% | 9.0% ▲0.0% | 9.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | ||||||||||
| Equity Capital | ₹20 Cr ▲0.0% | ₹20 Cr ▲0.0% | ₹20 Cr ▲0.0% | ₹20 Cr ▲0.0% | ₹20 Cr ▲0.0% | ₹20 Cr ▲0.0% | ₹20 Cr ▲0.0% | ₹20 Cr ▲0.0% | ₹20 Cr ▲0.0% | ₹20 Cr |
| Reserves | ₹696 Cr ▲6.7% | ₹652 Cr ▲13.8% | ₹573 Cr ▲18.9% | ₹482 Cr ▲16.7% | ₹413 Cr ▲19.4% | ₹346 Cr ▲18.1% | ₹293 Cr ▲17.7% | ₹249 Cr ▲22.1% | ₹204 Cr ▲18.6% | ₹172 Cr |
| Borrowings | ₹0 Cr | ₹0 Cr ▼100.0% | ₹1 Cr ▼50.0% | ₹2 Cr ▲0.0% | ₹2 Cr ▲100.0% | ₹1 Cr ▼80.0% | ₹5 Cr ▼85.3% | ₹34 Cr ▼44.3% | ₹61 Cr ▼4.7% | ₹64 Cr |
| Other Liabilities | ₹139 Cr ▲11.2% | ₹125 Cr ▲17.9% | ₹106 Cr ▲27.7% | ₹83 Cr ▼16.2% | ₹99 Cr ▲16.5% | ₹85 Cr ▲19.7% | ₹71 Cr ▲12.7% | ₹63 Cr ▲1.6% | ₹62 Cr ▲29.2% | ₹48 Cr |
| Total Liabilities | ₹855 Cr ▲7.3% | ₹797 Cr ▲13.9% | ₹700 Cr ▲19.3% | ₹587 Cr ▲9.9% | ₹534 Cr ▲18.1% | ₹452 Cr ▲16.2% | ₹389 Cr ▲6.3% | ₹366 Cr ▲5.5% | ₹347 Cr ▲13.8% | ₹305 Cr |
| Assets | ||||||||||
| Fixed Assets | ₹185 Cr ▲1.6% | ₹182 Cr ▲1.7% | ₹179 Cr ▲18.5% | ₹151 Cr ▲14.4% | ₹132 Cr ▲18.9% | ₹111 Cr ▼9.8% | ₹123 Cr ▲1.7% | ₹121 Cr ▲3.4% | ₹117 Cr ▲13.6% | ₹103 Cr |
| CWIP | ₹3 Cr ▼25.0% | ₹4 Cr ▲33.3% | ₹3 Cr ▼57.1% | ₹7 Cr ▼56.3% | ₹16 Cr ▲700.0% | ₹2 Cr | ₹0 Cr ▼100.0% | ₹2 Cr | ₹0 Cr ▼100.0% | ₹7 Cr |
| Investments | ₹209 Cr ▲20.1% | ₹174 Cr ▲25.2% | ₹139 Cr ▲52.7% | ₹91 Cr ▼6.2% | ₹97 Cr ▲19.8% | ₹81 Cr ▲138.2% | ₹34 Cr ▲88.9% | ₹18 Cr ▲63.6% | ₹11 Cr ▲10.0% | ₹10 Cr |
| Other Assets | ₹458 Cr ▲4.8% | ₹437 Cr ▲15.3% | ₹379 Cr ▲11.8% | ₹339 Cr ▲16.9% | ₹290 Cr ▲12.0% | ₹259 Cr ▲11.6% | ₹232 Cr ▲3.1% | ₹225 Cr ▲2.7% | ₹219 Cr ▲17.7% | ₹186 Cr |
| Total Assets | ₹855 Cr ▲7.3% | ₹797 Cr ▲13.9% | ₹700 Cr ▲19.3% | ₹587 Cr ▲9.9% | ₹534 Cr ▲18.1% | ₹452 Cr ▲16.2% | ₹389 Cr ▲6.3% | ₹366 Cr ▲5.5% | ₹347 Cr ▲13.8% | ₹305 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹93 Cr ▲47.6% | ₹63 Cr ▲61.5% | ₹39 Cr ▼48.7% | ₹76 Cr ▲10.1% | ₹69 Cr ▼8.0% | ₹75 Cr ▲41.5% | ₹53 Cr ▲96.3% | ₹27 Cr ▲8.0% | ₹25 Cr ▼44.4% | ₹45 Cr |
| Investing CF | ₹-79 Cr ▼38.6% | ₹-57 Cr ▼54.1% | ₹-37 Cr ▲52.6% | ₹-78 Cr ▼21.9% | ₹-64 Cr ▼106.5% | ₹-31 Cr ▼72.2% | ₹-18 Cr ▼50.0% | ₹-12 Cr ▲52.0% | ₹-25 Cr ▲40.5% | ₹-42 Cr |
| Financing CF | ₹-6 Cr ▼20.0% | ₹-5 Cr ▼25.0% | ₹-4 Cr ▼33.3% | ₹-3 Cr ▲50.0% | ₹-6 Cr ▲84.2% | ₹-38 Cr ▼5.6% | ₹-36 Cr ▼227.3% | ₹-11 Cr | ₹0 Cr ▲100.0% | ₹-3 Cr |
| Net Cash Flow | ₹8 Cr ▲700.0% | ₹1 Cr ▲150.0% | ₹-2 Cr ▲50.0% | ₹-4 Cr ▼300.0% | ₹-1 Cr ▼114.3% | ₹7 Cr ▲800.0% | ₹-1 Cr ▼133.3% | ₹3 Cr | ₹0 Cr | ₹0 Cr |
| Free Cash Flow | ₹74 Cr ▲208.3% | ₹24 Cr ▼7.7% | ₹26 Cr ▼16.1% | ₹31 Cr ▼49.2% | ₹61 Cr ▼10.3% | ₹68 Cr ▲78.9% | ₹38 Cr ▲123.5% | ₹17 Cr ▲142.9% | ₹7 Cr ▼36.4% | ₹11 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 97d ▼4.9% | 102d ▲4.1% | 98d ▲8.9% | 90d ▼8.2% | 98d ▲2.1% | 96d ▼21.3% | 122d ▲9.9% | 111d ▲20.7% | 92d ▲26.0% | 73d |
| Inventory Days | 99d ▼2.0% | 101d ▼4.7% | 106d ▼12.4% | 121d ▲40.7% | 86d ▼9.5% | 95d ▲26.7% | 75d ▼12.8% | 86d ▲36.5% | 63d ▲75.0% | 36d |
| Days Payable | 106d ▲11.6% | 95d ▲23.4% | 77d ▼35.8% | 120d ▲14.3% | 105d ▲2.9% | 102d ▲10.9% | 92d ▲12.2% | 82d ▲51.9% | 54d ▲35.0% | 40d |
| Cash Conv. Cycle | 90d ▼16.7% | 108d ▼14.3% | 126d ▲38.5% | 91d ▲16.7% | 78d ▼11.4% | 88d ▼17.0% | 106d ▼7.8% | 115d ▲15.0% | 100d ▲42.9% | 70d |
| Working Capital Days | 116d ▼4.1% | 121d ▲0.0% | 121d ▲7.1% | 113d ▼5.0% | 119d ▼5.6% | 126d ▲11.5% | 113d ▲27.0% | 89d ▲29.0% | 69d ▲122.6% | 31d |
| ROCE | 17.0% ▼22.7% | 22.0% ▲0.0% | 22.0% ▼8.3% | 24.0% ▼4.0% | 25.0% ▲13.6% | 22.0% ▼4.3% | 23.0% ▲21.1% | 19.0% ▲0.0% | 19.0% ▼9.5% | 21.0% |
Source: Screener.in · Lower days = better efficiency
Related Analysis
Frequently Asked Questions
What is Lincoln Pharmaceuticals Limited share price today?▾
Lincoln Pharmaceuticals Limited (LINCOLN) is currently trading at ₹625.55 on NSE, up 0.97% as of the last market session. Prices update daily after market close on MarketNetra.
Is Lincoln Pharmaceuticals Limited available in F&O (Futures & Options)?▾
Yes, Lincoln Pharmaceuticals Limited (LINCOLN) is part of the NSE F&O segment with a lot size of 1 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Lincoln Pharmaceuticals Limited 52-week high and low?▾
Lincoln Pharmaceuticals Limited's 52-week high is ₹770 and the 52-week low is ₹440. The current price of ₹625.55 is 18.8% below the 52W high.
What is Lincoln Pharmaceuticals Limited P/E ratio?▾
Lincoln Pharmaceuticals Limited's current P/E ratio is 13.3. This indicates the market is paying ₹13.3 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Lincoln Pharmaceuticals Limited options?▾
Lincoln Pharmaceuticals Limited options are traded on NSE with monthly expiry contracts (lot size: 1 shares). To trade LINCOLN options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.